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Abstract 
Lung cancer is the top cancer killer worldwide. Tyrosine kinase inhibitors (TKIs), for example 
erlotinib, are commonly used to target epidermal growth factor receptor (EGFR)-mutated lung 
adenocarcinoma (ADC). Autophagy is a cellular response to stress, serving as a protective 
mechanism during anticancer therapy. The tumor microenvironment (TME) is composed of 
non-tumor cells that include fibroblasts. Our study aimed to investigate the effect of TME on 
autophagy and TKI sensitivity. Following cell sorting after direct co-culturing, autophagy and cy-
tokine production were observed in both HCC827 and MRC-5 cells. The synergistic combination 
of erlotinib and chloroquine (autophagy inhibitor) was observed under TME. Tumor growth was 
significantly suppressed with combined erlotinib/chloroquine compared with erlotinib in HCC827 
xenografts. 
Key words: Tumor microenvironment, autophagy, tyrosine kinase inhibitors, non-small cell lung 
carcinoma 
Introduction 
Recently, we have shown that autophagy can be 
induced by erlotinib in EGFR-mutated lung adeno-
carcinoma (ADC) cells, while inhibition of autophagy 
with chloroquine or siRNA targeting key autophagic 
proteins enhances the apoptotic effect of erlotinib [1]. 
Nonetheless this cancer cell line model may only be a 
simplified representation of real-life lung cancer 
without the influence of the complex tumor microen-
vironment (TME). During tumor development, there 
are close interactions between tumor cells and the 
host leading to formation of a unique TME that is 
composed of different stromal cells, immune cells, 
vasculature and extracellular matrix. Through cross-
talk between different cells, TME participates in al-
most every stage of tumor development and results in 
increased tumor progression and metastatic potential 
[2, 3]. Few reports have described the association 
between autophagy and TME. In an experimental 
model of breast cancer cells co-cultured with fibro-
blasts, autophagy was induced in fibroblasts and 
contributed to cancer progression [4, 5]. The effect of 
TME on drug sensitivity in cancers has been demon-
strated in bone marrow stromal cells via mediators of 
CXCR4/SDF-1 axis, soluble factors and adhesion proteins 
[6]. Recently, hepatocyte growth factor produced by 
stromal fibroblasts has also been shown to render in 
vitro and in vivo resistance to EGFR TKI treatment in 
lung cancer [7]. 
In this study, we hypothesized that autophagy 
and cytokine production would occur in the presence 
of TME in an in vitro cell line model. The effects of an 
autophagic TME on TKI sensitivity in EGFR-mutated 
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lung ADC were investigated. Finally, the in vivo com-
bination effect of chloroquine (autophagy inhibitor) 
and erlotinib in EGFR-mutated lung ADC was stud-
ied in a tumor xenograft model.  
Materials and Methods 
Cell lines and cultures 
Human lung ADC HCC827 cells (EGFR exon 19 
deletion) and human lung fibroblast MRC-5 cells 
(American Type Culture Collection, Manassas, VA, 
USA) were obtained. For direct co-culture experi-
ments, MRC-5 and HCC827 cells were co-plated in 
6-well plates. MRC-5 cells were plated first, followed 
within 2 hours by HCC827 cells in 6-well plates. After 
co-culturing 7 days, cells were harvested for protein 
and RNA extraction [1, 8].  
Apoptotic assay  
Cells were incubated at 4oC in the dark for 1 hour 
with PE-conjugated annexin-V (BD biosciences, New 
Jersey, USA), PI and APC-conjugated EpCAM. Cells 
were then subjected to flow cytometry (Beckman 
Coulter, Inc., USA).  
Real-time polymerase chain reaction 
(RT-PCR) 
Total RNA was isolated using Trizol (Invitrogen, 
Life technologies). Reverse transcription was per-
formed using a Qiagen RT kit. Primers for IL-6, IL-8 
and GAPDH were synthesized (Tech Dragon Limited, 
HK): IL-6 forward and reverse primers 
(ATGCAATAACCACCCCTGAC and GAGGTGCCC 
ATGCTACATTT); IL-8 forward and reverse primers 
(TAGCAAAATTGAGGCCAAGG and AGGCACAG 
TGGAACAAGGAC); GAPDH forward and reverse 
primers (AGCCACATCGCTCAGACACC and GTAC 
TCAGCGCCAGCATCG). Amplification of targets 
was carried out using Power SYBR green PCR mix 
with Step One Plus Real-time PCR system (Applied 
Biosystems). Quantification of gene expression was 
calculated by the delta Ct method [9]. Data represent 
the mean ± SD of three independent experiments. 
Cell sorting experiments 
EpCAM is utilized as a surface marker to isolate 
lung cancer cells from cancer-associated fibroblasts 
[10]. After 7 days of co-culturing, cells were incubated 
with PE-conjugated anti-EpCAM antibody. 
PE-conjugated IgG Isotype was added to cells as a 
control for gating during cell sorting. EpCAM+ and 
EpCAM- cells were isolated by a BD fluores-
cence-activated cell sorting (FACS) Aria cell sorting 
system (BD Biosciences).  
  
HCC827 tumor xenograft model 
Tumor xenografts were established with 
HCC827 cells in nude mice (females, 4-weeks-old, 
10-12 grams, BALB/cAnN-nu, Charles River Labora-
tories, Wilmington, USA) [11]. Cells were mixed with 
matrigel matrix (BD Biosciences, USA) before being 
injected subcutaneously into the right flank of each 
mouse. Tumor diameter was measured with calipers 
and the volume calculated (volume = width x length x 
height/2) [12]. When the tumor volume reached 
about 100 mm3, the mice were divided into 4 treat-
ment groups: control (phosphate buffered saline) (n = 
9), erlotinib (25 mg/kg) (n = 8), chloroquine (50 
mg/kg) (n = 9) and combined erlotinb/chloroquine (n 
= 9). All treatments were administered by daily in-
traperitoneal injection. The growth curve was plotted 
for each group during 24 days of treatment. The study 
protocol was approved by the institutional Animal 
Ethics Committee (approval reference number: 
CULATR 2724-12) and standard humane endpoints 
for animal research were applied.  
Statistical analysis 
Data from triplicate experiments are presented 
in mean ± standard deviation (SD). Comparison be-
tween groups was performed using Student’s 
two-tailed t-test by Prism (GraphPad Software, La 
Jolla, Southern California, USA). A p-value <0.05 was 
considered statistically significant.  
Results 
Co-cultured cells were sorted into 2 populations 
(Figure 1A). After 7 days of co-culturing, IL-6 and IL-8 
mRNA was elevated (Figure 1B) and p62 expression 
was decreased (Figure 1C) in both sorted MRC-5 and 
HCC827 cells compared with their corresponding 
homotypical counterparts.  
In both MRC-5 and HCC827 cells, treatment with 
recombinant human IL-6 and IL-8 (20 ng/ml) and 
conditioned medium obtained after 7 days of 
co-culture decreased p62 expression and increased 
ATG5/12 conjugation. Dexamethasone (10 µM) de-
creased IL-6 and IL-8, followed by partial reversal of 
p62 downregulation in co-cultured cells (data not 
shown).  
PI-annexin-V and APC-EpCAM staining per-
formed on homotypical HCC827 cells and co-cultured 
cells indicated that 22% of homotypical HCC827 cells 
and 34.8% of co-cultured HCC827 cells underwent 
apoptosis. Combination of erlotinib and chloroquine 
potentiated apoptotic cell death in both homotypical 
and co-cultured HCC827 cells (Figure 2A).  
Progressive tumor growth was observed in con-
trol and treatment groups over 24 days of treatment. 
As expected, erlotinib alone significantly suppressed 
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tumor growth throughout the treatment period (p < 
0.05 on day 9 and 12; p < 0.001 from day 15 onwards). 
Combination of erlotinib and chloroquine resulted in 
even more significant tumor growth suppression than 
erlotinib alone (p < 0.01 on day 9 and 12; p < 0.001 
from day 15 onwards) (Figure 2B). In addition, in-
creased cleaved caspase-9 immunostaining was ob-
served with erlotinib/chloroquine combination com-
pared with either treatment alone or control (data not 
shown). 
Discussion 
In this study, we mimicked a TME by 
co-culturing HCC827 lung cancer cells with MRC-5 
fibroblasts. Cytokine elaboration and autophagy oc-
curred in both HCC827 and MRC-5 cells under 
co-culture conditions. The cytokines (IL-6 and IL-8) 
produced in TME served as one of the driving forces 
for autophagy. Nonetheless, sensitivity of HCC827 
cells to erlotinib was not dampened, and combined 
chloroquine and erlotinib induced more apoptotic cell 
death compared with erlotinib alone in TME. Syner-
gism between chloroquine and erlotinib was also 
demonstrated using a HCC827 xenograft model.  
Co-culturing of tumor cells with stromal cells [4] 
allowing in vitro interactions between cancer cells and 
neighboring cells or soluble factors. Cancer-associated 
fibroblasts are often studied by co-culturing with ini-
tiated human epithelial cells, conferring faster growth 
kinetics and tumor progression in the epithelial 
component [13].  
 
Figure 1. Cytokine production and autophagy induction in both MRC-5 and HCC827 cells in the tumor microenvironment. (A) After staining for EpCAM, the 
co-cultured cells were divided into 2 populations. (B) The IL-6 and IL-8 mRNA expression in sorted cells was significantly increased compared with corresponding 
homotypical cells. (C) Autophagy was induced in sorted cells compared with their homotypical counterparts, as evidenced by p62 degradation. Western blot data 
were quantified by fold-change compared with homotypical MRC-5 cells or homotypical HCC827 cells. Comparisons are made between sorted cells with respective 
homotypical cells. Statistical significance (*: p <0.05, **: p <0.01) indicates comparison with control. 
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Figure 2. (A) Apoptosis in HCC827 or co-cultured HCC827 cells after 
erlotinib ± chloroquine treatment. In homotypical HCC827 cells, combination 
of erlotinib with chloroquine significantly increased apoptotic cell death com-
pared with erlotinib alone. In co-culture conditions, the sensitivity to erlotinib 
was preserved and synergistic combination of erlotinib/chloroquine was evi-
dent. Statistical significance (*: p <0.05, **: p <0.01) indicates comparison with 
control. (B) Antitumor effect of erlotinib, chloroquine (CQ) or combined 
erlotinib/CQ in a HCC827 xenograft model in nude mice. Longitudinal tumor 
size with different treatment groups. The relative tumor volume was calculated 
as fold-change to the baseline tumor volume prior to treatment. Progressive 
tumor growth was noted in both control and CQ treatment group, while 
significant tumor growth suppression was evident in erlotinib treatment and 
combination group. Statistical significance (*: p <0.05, **: p <0.01) indicates 
comparison between erlotinib with control and combination with erlotinib.  
 
By directly co-culturing MRC-5 with HCC827 
cells, an activated TME was generated. This finding 
differed to a prostatic cancer model wherein only 
stromal fibroblasts could drive tumor progression by 
co-culturing with prostatic epithelial cells [14], but 
was consistent with a previous breast cancer model 
[4]. Our findings suggest the presence of intermingled 
interactions between lung tumor cells and fibroblasts 
in TME.  
Autophagy status in tumors is highly dependent 
on tumor type and stage [15]. Interestingly, autopha-
gy occurred in both cancerous and stromal compart-
ments of the TME, and might provide new insight 
into the possible relationship between autophagy and 
TME. Nonetheless previous studies have only 
demonstrated autophagy induction in can-
cer-associated fibroblasts via oxidative stress derived 
from cancer cells [5]. The possible role of elaborated 
cytokines in TME on autophagy was also studied. 
Exogenous application of IL-6 or IL-8 increased 
ATG5/12 conjugation and decreased p62 in both 
HCC827 and MRC-5 cells, indicating cyto-
kine-induced autophagy in TME. Pretreatment with 
dexamethasone, an anti-inflammatory agent shown to 
downregulate IL-6 and IL-8 expression in fibroblasts 
[16], partially reversed p62 degradation in the 
co-culture condition, supporting the contributory role 
of cytokines to heightened autophagy in TME.  
Stromal fibroblasts have been implicated in the 
development of EGFR TKI resistance in lung cancer 
[7, 17, 18]. Nonetheless our findings suggest that TKI 
sensitivity of EGFR-mutated lung ADC is not reduced 
in the presence of TME. Increased cytokines in our 
TME model may contribute to other cancer-related 
characteristics, such as metastasis and aggressiveness 
[19], rather than TKI resistance. On the other hand, 
sensitivity to erlotinib and synergistic combination of 
chloroquine/erlotinib was consistently demonstrated 
in our HCC827 xenograft model.  
There are two limitations of our study. First, we 
used only a single lung ADC cell line in our in vitro 
and in vivo model. Second, other components of TME 
(e.g. vasculature, immunological cells) have not been 
studied.  
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